Mosenzon O, et al. - In patients with type 2 diabetes, researchers analyzed the impacts of dapagliflozin on development and progression of kidney disease. For this investigation, subjects with type 2 diabetes, HbA1c 6.5–12.0% (47.5–113.1 mmol/mol), with either established atherosclerotic cardiovascular disease or multiple risk factors, and creatinine clearance of at least 60 mL/min were randomized (1:1) to 10 mg dapagliflozin or placebo once daily. In this large and diverse population of patients with type 2 diabetes with and without established atherosclerotic cardiovascular disease, most of whom had preserved renal function, dapagliflozin appeared to prevent and decrease the progression of kidney disease vs placebo.